Clinical review report: Eculizumab (Soliris) Alexion Pharma Canada corporation : indication : adult patients with generalized myasthenia gravis
The objective of this report is to perform a systematic review of the beneficial and harmful effects of eculizumab for the treatment of adult patients who are AChR-antibody-positive and have refractory generalized myasthenia gravis, defined as having failed treatment with at least two immunosuppress...
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2020, December 2020
|
Edition: | Version: Final (with redactions) |
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references